Month: December 2017

Genomics England appoints two new Non-Executive Directors to its Board – to build strategic, medical and commercial strength

Genomics England has announced the appointment of two new Non-Executive members to its Board. Sir Ron Kerr and Keith Stewart bring a wealth of senior scientific, commercial and managerial experience to Genomics England − providing effective support for the strategic and operational leadership of the organisation.

Genomics England’s new Non-Executive Directors bring highly relevant professional expertise and the ability to engage with stakeholders at every level. They are tasked to ensure the on-going pace, innovation and impact of Genomics England’s pioneering work, helping to plan for the future as it progresses beyond the 100,000 Genomes Project:

Sir Ron Kerr

  • Sir Ron Kerr is currently: a Special Adviser to the Board at Guy’s and St Thomas’ NHS Foundation Trust – with a particular focus on commercial issues; Non-Executive Chair of the Bristol, North Somerset and South Gloucestershire Sustainability and Transformation Partnership (STP); Member, Board of Trustees, University of Bristol; and Member, Board of Trustees of the Guy’s and St Thomas’ Charity. His career spans 40 years – including CEO at the National Care Standards Commission and senior leadership roles across the NHS. Sir Ron is married with three children and was knighted in 2011 for services to the NHS.

Keith Stewart

  • Keith Stewart brings an internationally recognised reputation as a leader in the field of genomics. He is currently: Professor of Medicine at the Mayo Clinic College of Medicine and Science (US); Consultant – Division of Hematology/Oncology, Department of Internal Medicine (Mayo Clinic); Vasek and Anna Maria Polak Professor of Cancer Research (Mayo Clinic); Carlson and Nelson Endowed Director – Center for Individualized Medicine (Mayo Clinic); and Consultant – Department of Clinical Genomics (Mayo Clinic). Keith brings a focus on the clinical applications of genomics, sits on a number of scientific advisory boards and has considerable interest in business development activities – setting up two biotech start-ups and holding a number of patents.

Genomics England Executive Chair, Sir John Chisholm, said:

“Sir Ron Kerr and Keith Stewart join Genomics England at a critical moment. Between them they bring deep experience − of the NHS, cutting-edge genomic medicine and commercial opportunity. Their appointment to the Genomics England Board gives us invaluable insight – both as the NHS is on the cusp of introducing the world’s first genomic medicine service and we work to make the UK the global centre of genomics research, innovation and investment.” 

Sir Ron Kerr said:

“As someone who believes fundamentally in the value and potential of the NHS, I am delighted to join Genomics England.  As a Non-Executive Director I hope I can provide some helpful insight and advice that will help to drive true transformation – harnessing that power of genomic medicine for the benefit of patients in the UK and around the world.”

Keith Stewart said:

“Genomics England is an acknowledged global leader in the field of genomic medicine and I am excited by its potential. I will use my experience in translating genomic medicine in the clinic to help this groundbreaking organisation develop and grow ¬– creating new opportunities for patients, the NHS and the UK economy.”

Genomics England welcomes the UK Life Sciences Sector Deal

In response to yesterday’s Life Sciences Sector Deal announcement from the UK government, Sir John Chisholm, Executive Chair of Genomics England said:

“I warmly welcome the UK Life Sciences Sector Deal announced on 6 December – and congratulate Sir John Bell and all of those who have created a transformative roadmap for Life Sciences in the UK.

From the outset, Genomics England has worked to translate the UK’s world leading genomic research into a vibrant UK genomics industry. The Life Sciences Sector Deal recognises and builds on the progress that Genomics England has made in aligning pioneering science with the needs of industry to make the UK the global centre of genomics research, discovery and investment.

The Life Sciences Sector Deal represents a bold ‘green light’ from Government – placing genomic discovery at the heart of the Life Sciences. We are committed to seizing this once in a generation opportunity – furthering our deep industry partnerships to help transform the NHS, bring benefit to patients and drive UK economic growth.”

View our Industry Partnerships pages

Alex’s Story

View in new tab

In this video, meet participant Alexander Masterson and his mum, Kirsty, who speak about what getting a diagnosis from the 100,000 Genomes Project means to them.

Find out about the rare disease that he was diagnosed with as a child, Noonan syndrome, and how his recent genetic diagnosis of LEOPARD syndrome is changing their view.

Hear from Alex about his experiences of living with his rare disease, as well as his plans for the future.

Thank you to Alex and Kirsty for sharing their story.

Meet more participants

All NHS GMC Contacts | South London NHS GMC